Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Immune Cell Composition in Human Non-small Cell Lung Cancer.

Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A.

Front Immunol. 2019 Feb 1;9:3101. doi: 10.3389/fimmu.2018.03101. eCollection 2018.

2.

Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation.

Müller E, Speth M, Christopoulos PF, Lunde A, Avdagic A, Øynebråten I, Corthay A.

Front Immunol. 2018 Nov 2;9:2520. doi: 10.3389/fimmu.2018.02520. eCollection 2018.

3.

CD4+ T-cell-Mediated Rejection of MHC Class II-Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs.

Haabeth OAW, Fauskanger M, Manzke M, Lundin KU, Corthay A, Bogen B, Tveita AA.

Cancer Res. 2018 Aug 15;78(16):4573-4585. doi: 10.1158/0008-5472.CAN-17-2426. Epub 2018 May 11.

PMID:
29752262
4.

Structural characterization of bioactive heteropolysaccharides from the medicinal fungus Inonotus obliquus (Chaga).

Wold CW, Kjeldsen C, Corthay A, Rise F, Christensen BE, Duus JØ, Inngjerdingen KT.

Carbohydr Polym. 2018 Apr 1;185:27-40. doi: 10.1016/j.carbpol.2017.12.041. Epub 2017 Dec 20.

PMID:
29421057
5.

Generation and Functional In Vitro Analysis of Semliki Forest Virus Vectors Encoding TNF-α and IFN-γ.

Kurena B, Müller E, Christopoulos PF, Johnsen IB, Stankovic B, Øynebråten I, Corthay A, Zajakina A.

Front Immunol. 2017 Nov 30;8:1667. doi: 10.3389/fimmu.2017.01667. eCollection 2017.

6.

Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics.

Christopoulos PF, Corthay A, Koutsilieris M.

Cancer Treat Rev. 2018 Feb;63:79-95. doi: 10.1016/j.ctrv.2017.11.010. Epub 2017 Dec 6. Review.

PMID:
29253837
7.

Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages.

Müller E, Christopoulos PF, Halder S, Lunde A, Beraki K, Speth M, Øynebråten I, Corthay A.

Front Immunol. 2017 Oct 26;8:1383. doi: 10.3389/fimmu.2017.01383. eCollection 2017.

8.

Poly(I:C)-Encapsulating Nanoparticles Enhance Innate Immune Responses to the Tuberculosis Vaccine Bacille Calmette-Guérin (BCG) via Synergistic Activation of Innate Immune Receptors.

Speth MT, Repnik U, Müller E, Spanier J, Kalinke U, Corthay A, Griffiths G.

Mol Pharm. 2017 Nov 6;14(11):4098-4112. doi: 10.1021/acs.molpharmaceut.7b00795. Epub 2017 Oct 19.

PMID:
28974092
9.

Immune Class Regulation and Its Medical Significance Part II of a Report of a Workshop on Foundational Concepts of Immune Regulation.

Bretscher PA, Corthay A, Anderson CC, Dembic Z, Havele C, Nagy ZA, Øynebråten I.

Scand J Immunol. 2017 Apr;85(4):242-250. doi: 10.1111/sji.12525.

10.

Immunological Tolerance. Part I of a Report of a Workshop on Foundational Concepts of Immune Regulation.

Anderson CC, Bretscher P, Corthay A, Dembic Z, Havele C, Nagy ZA, Øynebråten I.

Scand J Immunol. 2017 Feb;85(2):84-94. doi: 10.1111/sji.12500.

11.

Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response.

Lorvik KB, Hammarström C, Fauskanger M, Haabeth OA, Zangani M, Haraldsen G, Bogen B, Corthay A.

Cancer Res. 2016 Dec 1;76(23):6864-6876. Epub 2016 Sep 12.

12.

Coupling of HIV-1 Antigen to the Selective Autophagy Receptor SQSTM1/p62 Promotes T-Cell-Mediated Immunity.

Andersen AN, Landsverk OJ, Simonsen A, Bogen B, Corthay A, Øynebråten I.

Front Immunol. 2016 May 10;7:167. doi: 10.3389/fimmu.2016.00167. eCollection 2016.

13.

Book Review: Rediscovering the Immune System as an Integrated Organ.

Corthay A.

Scand J Immunol. 2016 Jul;84(1):70-1. doi: 10.1111/sji.12440. Review.

14.

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue.

Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A.

F1000Res. 2016 Jan 8;5:38. doi: 10.12688/f1000research.7599.1. eCollection 2016.

15.

Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells.

Haabeth OA, Lorvik KB, Yagita H, Bogen B, Corthay A.

Oncoimmunology. 2015 Jul 25;5(1):e1039763. eCollection 2016.

16.

Does the immune system naturally protect against cancer?

Corthay A.

Front Immunol. 2014 May 12;5:197. doi: 10.3389/fimmu.2014.00197. eCollection 2014. Review.

17.

How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B.

Front Immunol. 2014 Apr 15;5:174. doi: 10.3389/fimmu.2014.00174. eCollection 2014. Review.

18.

Molecular profiling of tumor-specific TH1 cells activated in vivo.

Lorvik KB, Haabeth OA, Clancy T, Bogen B, Corthay A.

Oncoimmunology. 2013 May 1;2(5):e24383.

19.

A model for cancer-suppressive inflammation.

Haabeth OA, Bogen B, Corthay A.

Oncoimmunology. 2012 Oct 1;1(7):1146-1155.

20.

SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice.

Berge T, Grønningsæter IH, Lorvik KB, Abrahamsen G, Granum S, Sundvold-Gjerstad V, Corthay A, Bogen B, Spurkland A.

PLoS One. 2012;7(10):e48239. doi: 10.1371/journal.pone.0048239. Epub 2012 Oct 29.

21.

Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice.

Lorvik KB, Bogen B, Corthay A.

Blood. 2012 Mar 1;119(9):2176-7. doi: 10.1182/blood-2011-10-388892. No abstract available.

22.

Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer.

Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, Corthay A.

Nat Commun. 2011;2:240. doi: 10.1038/ncomms1239.

23.

Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.

Corthay A, Lorvik KB, Bogen B.

Scand J Immunol. 2011 Jun;73(6):527-30. doi: 10.1111/j.1365-3083.2011.02558.x. Review.

24.

How do regulatory T cells work?

Corthay A.

Scand J Immunol. 2009 Oct;70(4):326-36. doi: 10.1111/j.1365-3083.2009.02308.x. Review.

25.

Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.

Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B.

Cancer Res. 2009 Jul 15;69(14):5901-7. doi: 10.1158/0008-5472.CAN-08-4816. Epub 2009 Jun 30.

26.

Isoform-specific regulation of immune cell reactivity by the catalytic subunit of protein kinase A (PKA).

Funderud A, Aas-Hanssen K, Aksaas AK, Hafte TT, Corthay A, Munthe LA, Orstavik S, Skålhegg BS.

Cell Signal. 2009 Feb;21(2):274-81. doi: 10.1016/j.cellsig.2008.10.013. Epub 2008 Oct 29.

PMID:
19000925
27.

CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells.

Corthay A.

Adv Exp Med Biol. 2007;590:195-208. Review. No abstract available.

PMID:
17191387
28.

A three-cell model for activation of naïve T helper cells.

Corthay A.

Scand J Immunol. 2006 Aug;64(2):93-6. Review.

29.

Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research.

Bogen B, Ruffini PA, Corthay A, Fredriksen AB, Frøyland M, Lundin K, Røsjø E, Thompson K, Massaia M.

Haematologica. 2006 Jul;91(7):941-8. Review.

30.

Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells.

Munthe LA, Corthay A, Os A, Zangani M, Bogen B.

J Immunol. 2005 Aug 15;175(4):2391-400.

31.

Primary antitumor immune response mediated by CD4+ T cells.

Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B.

Immunity. 2005 Mar;22(3):371-83.

32.

Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models.

Corthay A, Lundin KU, Munthe LA, Frøyland M, Gedde-Dahl T, Dembic Z, Bogen B.

Cancer Immunol Immunother. 2004 Sep;53(9):759-69. Epub 2004 Apr 15. Review.

PMID:
15088126
33.

Monoclonal antibodies produced by muscle after plasmid injection and electroporation.

Tjelle TE, Corthay A, Lunde E, Sandlie I, Michaelsen TE, Mathiesen I, Bogen B.

Mol Ther. 2004 Mar;9(3):328-36.

34.

Role of gamma/delta T cell receptor-expressing lymphocytes in cutaneous infection caused by Staphylococcus aureus.

Mölne L, Corthay A, Holmdahl R, Tarkowski A.

Clin Exp Immunol. 2003 May;132(2):209-15.

35.

Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies.

Lundin KU, Hofgaard PO, Omholt H, Munthe LA, Corthay A, Bogen B.

Blood. 2003 Jul 15;102(2):605-12. Epub 2003 Mar 20.

37.
38.
39.
40.

Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis.

Corthay A, Bäcklund J, Broddefalk J, Michaëlsson E, Goldschmidt TJ, Kihlberg J, Holmdahl R.

Eur J Immunol. 1998 Aug;28(8):2580-90.

Supplemental Content

Loading ...
Support Center